Profile: ChemBridge Research Laboratories, Inc.
BioHealth Investor Company Directory Profile
ChemBridge Research Laboratories, Inc.
16981 Via Tazon, Suite K
San Diego, CA 92127
Phone: (858)485-9900
Fax: (858)485-9922
Founded in 2000 as a spin-off of ChemBridge Corporation, CRL now has 38 employees (33 scientists, 19 Ph.D. chemists) led by research management with substantial experience in the pharmaceutical and biotech industries. The company is located in San Diego in custom-built, state-of-the-art research facilities. While also providing advanced library development and medchem support research services, CRL focuses on collaborative and internal medicinal chemistry, hit-to-lead, and lead-optimization programs.
CRL has an integrated, comprehensive medicinal chemistry platform. The medicinal chemists are supported by high-throughput, large-scale, analytical, and computational chemistry; high-throughput purification; a company-wide proprietary cheminformatics system; bioassay development; and screening capabilities. In addition to its own substantial resources, CRL has preferential access, as needed, to ChemBridge’s (its parent company) premier screening library of 600,000 small molecule compounds, its extensive proprietary building block portfolio, and its cost-effective offshore chemistry resources.
CRL's business model balances internal drug discovery programs with revenue-generating chemistry research collaborations, several of which have downstream potential. CRL's steady revenue growth allowed the company to become cash positive, while continually increasing research personnel and investment in its own promising proprietary discovery pipeline.
CRL consistently exceeds the goals and expectations on its discovery chemistry collaborations, including its major, multi-year strategic alliances with Merck & Co. and Pfizer. The Pfizer collaboration was recently expanded and extended through 2008. CRL's partners also include Eisai, GlaxoSmithKline, GNF/Novartis, Memorial Sloan–Kettering Cancer Center, Merck KGaA, MethylGene, Tanabe, and Tularik/Amgen. CRL collaborates on the most challenging, research-intensive medicinal chemistry support, hit-to-lead, and lead-optimization projects. This positions CRL as a recognized preferred partner for pharmaceutical and biotech companies that want to strengthen and expand their chemistry expertise and capabilities in small molecule drug discovery.
CRL's own drug discovery efforts encompass two oncology targets and one obesity target. These efforts leverage the company's proprietary targeted library portfolio and its core internal expertise in kinase and GPCR drug target classes. CRL's most promising discovery program focuses on the high-profile oncology target, IGF1R, which is a validated target for treatment of multiple myelomas and solid tumors. An undisclosed major US clinical oncology research center is collaborating with CRL to discover small molecule IGF1R inhibitors. CRL retains the majority of the intellectual property rights for this program.
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
ChemBridge Research Laboratories, Inc. 16981 Via Tazon, Suite K
San Diego, CA 92127
Phone: (858)485-9900
Fax: (858)485-9922
Founded in 2000 as a spin-off of ChemBridge Corporation, CRL now has 38 employees (33 scientists, 19 Ph.D. chemists) led by research management with substantial experience in the pharmaceutical and biotech industries. The company is located in San Diego in custom-built, state-of-the-art research facilities. While also providing advanced library development and medchem support research services, CRL focuses on collaborative and internal medicinal chemistry, hit-to-lead, and lead-optimization programs.
CRL has an integrated, comprehensive medicinal chemistry platform. The medicinal chemists are supported by high-throughput, large-scale, analytical, and computational chemistry; high-throughput purification; a company-wide proprietary cheminformatics system; bioassay development; and screening capabilities. In addition to its own substantial resources, CRL has preferential access, as needed, to ChemBridge’s (its parent company) premier screening library of 600,000 small molecule compounds, its extensive proprietary building block portfolio, and its cost-effective offshore chemistry resources.
CRL's business model balances internal drug discovery programs with revenue-generating chemistry research collaborations, several of which have downstream potential. CRL's steady revenue growth allowed the company to become cash positive, while continually increasing research personnel and investment in its own promising proprietary discovery pipeline.
CRL consistently exceeds the goals and expectations on its discovery chemistry collaborations, including its major, multi-year strategic alliances with Merck & Co. and Pfizer. The Pfizer collaboration was recently expanded and extended through 2008. CRL's partners also include Eisai, GlaxoSmithKline, GNF/Novartis, Memorial Sloan–Kettering Cancer Center, Merck KGaA, MethylGene, Tanabe, and Tularik/Amgen. CRL collaborates on the most challenging, research-intensive medicinal chemistry support, hit-to-lead, and lead-optimization projects. This positions CRL as a recognized preferred partner for pharmaceutical and biotech companies that want to strengthen and expand their chemistry expertise and capabilities in small molecule drug discovery.
CRL's own drug discovery efforts encompass two oncology targets and one obesity target. These efforts leverage the company's proprietary targeted library portfolio and its core internal expertise in kinase and GPCR drug target classes. CRL's most promising discovery program focuses on the high-profile oncology target, IGF1R, which is a validated target for treatment of multiple myelomas and solid tumors. An undisclosed major US clinical oncology research center is collaborating with CRL to discover small molecule IGF1R inhibitors. CRL retains the majority of the intellectual property rights for this program.
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
posted by Nico at
12:42 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home